Drug Profile
Nitroglycerin-transdermal - Novosis Pharma AG
Latest Information Update: 21 Jul 2004
Price :
$50
*
At a glance
- Originator Novosis Pharma
- Class
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 21 Jul 2004 No development reported - Preclinical for Angina pectoris in Germany (Transdermal)
- 21 Nov 2001 New profile
- 21 Nov 2001 Preclinical development for Angina pectoris in Germany (Transdermal)